Cardiovascular toxicity is a potential short and long-term complication of anti-cancer therapy with DOX+TRZ in the breast cancer setting. Although FLX is commonly consumed in up to 30% of women with breast cancer to improve overall disease burden and survival, it is important to study whether this natural dietary agent can also reduce the cardiotoxic side effects of DOX+TRZ in the clinical setting. The investigators hypothesize that the prophylactic consumption of FLX "milk" will prevent adverse cardiovascular remodeling and improve overall functional capacity in women with breast cancer receiving DOX+TRZ therapy. The two specific aims of the CANFLAX study include: Aim 1: FLX "milk" will prevent the development of heart failure in women with early stage breast cancer (EBC) who are treated with DOX+TRZ based chemotherapy; and Aim 2: FLX "milk" will improve cardiac functional capacity in this patient population.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
i) ≥18 years old;
ii) women with newly diagnosed early stage breast cancer (Stage I-IIIA)
iii) chemotherapy with 5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or adriamycin and cyclophosphamide (AC) for 4 months
You may not be if
i) pre-existing diagnosis of heart failure and/or LVEF\<40%
ii) pre-existing use of anti-hypertensive agents including ACE inhibitors (ACEi) or beta blockers
iii) planned use of any herbal/antioxidant/fatty acid/nutritional supplements at any time in the duration of the study.
Clareo Health | Can Flaxseed Prevent Broken Hearts in Women With Breast Cancer Study?
